Found 12 clinical trials
-
Phase 3 trial
-
Accepting adults
-
For all genders
-
Neurology
-
Currently Recruiting
A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy
This study will look to see if ofatumumab works and is safe in adults with relapsing multiple sclerosis (MS) who are switching from their current oral medicines (dimethyl fumarate or fingolimod
- 0 views
- 27 Jan, 2021
- 1 location
-
Phase 4 trial
-
Accepting adults
-
For all genders
-
Currently Recruiting
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
- 74 views
- 25 Mar, 2021
- 1 location
-
Multi-country trial
-
Phase 3 trial
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab
The open label study to evaluate effectiveness of treatment with ofatumumab in patients transitioning from commonly used oral MS therapies - fingolimod or dimethyl fumarate, due to breakthrough
- 0 views
- 10 Apr, 2021
- 90 locations
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Long-term Safety Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS
- 234 views
- 11 Apr, 2021
- 261 locations
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Family Medicine
-
Currently Recruiting
A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment
The purpose of this study is to compare ofatumumab & chlorambucil (O-Chl) versus ofatumumab & bendamustine (O-B) in patients with Chronic Lymphocytic Leukaemia who are considered not fit
- 436 views
- 08 Nov, 2020
- 1 location
-
Phase 4 trial
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
To assess whether participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once every 4 weeks (q4) can mount an adequate immune response to inactivated influenza vaccine as
- 0 views
- 28 Mar, 2021
- 1 location
-
Multi-country trial
-
Phase 3 trial
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Single Arm Study Evaluating the Efficacy Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis who are transitioning from aCD20 mAb therapy
- 0 views
- 08 Apr, 2021
- 8 locations
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Family Medicine
-
Currently Recruiting
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
ofatumumab, having a more potent anti-CLL activity and complement-dependent cytoxicity than rituximab, could improve disease control and modulate the GVCLL effect more effectively, thus reducing
- 12 views
- 08 Nov, 2020
- 2 locations
-
Phase 2 trial
-
Accepting pediatric ages
-
Accepting Seniors
-
10s of participants
-
An interventional trial
-
For all genders
-
Hematology
-
Currently Recruiting
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
combination with ofatumumab or rituximab in treating patients with Burkitt lymphoma that is newly diagnosed, or has returned after a period of improvement (relapsed), or has not responded to previous
- 5 views
- 24 Jan, 2021
- 2 locations
-
Phase 2 trial
-
Accepting pediatric ages
-
Accepting Seniors
-
10s of participants
-
An interventional trial
-
For all genders
-
Family Medicine
-
Currently Recruiting
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma Burkitt Lymphoma/Leukemia or Double-Hit Lymphoma/Leukemia
This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt lymphoma/leukemia, or double-hit lymphoma/leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as clofarabine, etoposide, cyclophosphamide, vincristine sulfate liposome, …
- 22 views
- 24 Jan, 2021
- 2 locations
- 1
- 2